Table 2.
Cox proportional analysis pre-immunization
| Risk to be treated after CHMI | ||||||
|---|---|---|---|---|---|---|
| Cell frequency (Pre-immunization) | Estimated cell number (Pre-immunization) | |||||
| HR | 95%CI | p value | HR | 95%CI | p value | |
| IFNγ+IL2+TNFα+ CD4+ T | 1.49 | 0.92–2.40 | 0.10 | 1.02 | 0.99–1.04 | 0.13 |
| IFNγ+IL2+ CD4+ T | 0.92 | 0.52–1.64 | 0.78 | 0.98 | 0.79–1.20 | 0.86 |
| IFNγ+TNFα+ CD4+ T | 1.28 | 0.46–3.55 | 0.63 | 0.99 | 0.95–1.03 | 0.85 |
| IL2+TNFα+ CD4+ T | 1.15 | 0.58–2.27 | 0.68 | 1.00 | 0.99–1.01 | 0.56 |
| IgG positive CD20 + B cell | 0.85 | 0.56–1.10 | 0.16 | 1.00 | 0.99–1.00 | 0.59 |
| GMZ2-specific B cells | 1.01 | 0.94–1.1 | 0.64 | 1.00 | 0.99–1.00 | 0.07 |
| CD27 negative GMZ2-specific B cells | 1.01 | 0.91–1.12 | 0.74 | 1.00 | 0.99–1.00 | 0.21 |
| CD27 positive GMZ2-specific B cells | 1.39 | 0.98–1.96 | 0.06 | 1.01 | 0.99–1.02 | 0.07 |
Treatment after CHMI was administered to those who developed malaria or to those whose parasitaemia was more than 1000 parasites per µL.
p value was significant when less than 0.05
CI confidence interval, HR hazard ratio.